Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 5 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Monopar Therapeutics changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 18 | 35 | +17 |
| Shares | 2.58M | 2.89M | +307.7K (+11.9%) |
| Value | $57.1M | $109.4M | +$52.2M (+91.5%) |
New holders (18)
Institutions that held Monopar Therapeutics at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Affinity Asset Advisors, LLC | 62,000 | $2.26M | 0.35% |
| Millennium Management LLC | 60,367 | $2.20M | 0.00% |
| Marshall Wace, LLP | 25,988 | $946.2K | 0.00% |
| Goldman Sachs Group Inc | 18,480 | $672.9K | 0.00% |
| State Street Corp | 15,814 | $575.8K | 0.00% |
| Jane Street Group, LLC | 10,357 | $377.1K | 0.00% |
| Northern Trust Corp | 9,161 | $333.6K | 0.00% |
| Omers Administration Corp | 9,000 | $327.7K | 0.00% |
| HRT Financial LP | 8,228 | $299.0K | 0.00% |
| Balyasny Asset Management LLC | 6,141 | $223.6K | 0.00% |
| Gerber, LLC | 5,601 | $203.9K | 0.17% |
| Point72 Asia (Singapore) Pte. Ltd. | 1,761 | $64.1K | 0.02% |
| Quest Partners LLC | 1,215 | $44.2K | 0.00% |
| Citigroup Inc | 225 | $8.19K | 0.00% |
| Point72 (DIFC) Ltd | 196 | $7.13K | 0.00% |
| Royal Bank of Canada | 205 | $7.00K | 0.00% |
| Allworth Financial LP | 100 | $4.46K | 0.00% |
| Barclays PLC | 12 | $437 | 0.00% |
Sold out (1)
Institutions that held Monopar Therapeutics at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| SBI Securities Co., Ltd. | 100 | $2.20K |